West Pharmaceutical Services Inc. (NYSE:WST) Stock Position Lifted by TD Asset Management Inc.

Share on StockTwits

TD Asset Management Inc. boosted its stake in shares of West Pharmaceutical Services Inc. (NYSE:WST) by 5.4% during the second quarter, HoldingsChannel.com reports. The firm owned 118,305 shares of the medical instruments supplier’s stock after acquiring an additional 6,110 shares during the period. TD Asset Management Inc.’s holdings in West Pharmaceutical Services were worth $14,806,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. BlackRock Inc. lifted its stake in shares of West Pharmaceutical Services by 2.5% in the first quarter. BlackRock Inc. now owns 7,111,791 shares of the medical instruments supplier’s stock worth $783,720,000 after buying an additional 172,298 shares during the last quarter. WCM Investment Management LLC lifted its stake in shares of West Pharmaceutical Services by 1.2% in the first quarter. WCM Investment Management LLC now owns 1,122,116 shares of the medical instruments supplier’s stock worth $123,658,000 after buying an additional 13,448 shares during the last quarter. Artisan Partners Limited Partnership lifted its stake in shares of West Pharmaceutical Services by 0.5% in the first quarter. Artisan Partners Limited Partnership now owns 1,111,465 shares of the medical instruments supplier’s stock worth $122,483,000 after buying an additional 5,052 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of West Pharmaceutical Services by 5.1% in the first quarter. Janus Henderson Group PLC now owns 962,252 shares of the medical instruments supplier’s stock worth $106,040,000 after buying an additional 46,338 shares during the last quarter. Finally, Bessemer Group Inc. lifted its stake in shares of West Pharmaceutical Services by 0.3% in the second quarter. Bessemer Group Inc. now owns 779,440 shares of the medical instruments supplier’s stock worth $97,548,000 after buying an additional 2,270 shares during the last quarter. 91.76% of the stock is currently owned by hedge funds and other institutional investors.

WST has been the subject of a number of analyst reports. William Blair initiated coverage on shares of West Pharmaceutical Services in a research note on Tuesday, April 23rd. They issued an “outperform” rating and a $112.16 price objective for the company. Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating and set a $158.00 price objective for the company in a research note on Saturday, August 3rd. Bank of America upgraded shares of West Pharmaceutical Services from an “underperform” rating to a “neutral” rating in a research note on Friday, July 26th. Finally, Jefferies Financial Group cut shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $122.00 price objective for the company. in a research note on Wednesday, May 1st. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. West Pharmaceutical Services has an average rating of “Buy” and an average target price of $130.72.

NYSE:WST traded up $2.18 during trading hours on Friday, hitting $145.06. 152,400 shares of the company traded hands, compared to its average volume of 406,441. The stock has a market capitalization of $10.54 billion, a price-to-earnings ratio of 51.62, a P/E/G ratio of 4.07 and a beta of 1.30. West Pharmaceutical Services Inc. has a twelve month low of $91.75 and a twelve month high of $145.17. The firm has a 50-day moving average of $130.78 and a 200 day moving average of $117.03. The company has a current ratio of 3.02, a quick ratio of 2.27 and a debt-to-equity ratio of 0.18.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 25th. The medical instruments supplier reported $0.89 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.72 by $0.17. The firm had revenue of $469.70 million during the quarter, compared to analysts’ expectations of $459.90 million. West Pharmaceutical Services had a net margin of 12.94% and a return on equity of 16.93%. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.70 EPS. Equities research analysts predict that West Pharmaceutical Services Inc. will post 3.07 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 6th. Investors of record on Wednesday, October 23rd will be paid a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.41%. The ex-dividend date is Tuesday, October 22nd. West Pharmaceutical Services’s payout ratio is currently 21.35%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

See Also: Buyback For Investors Defined

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.